Article

Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models

2025-03-01

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Colorectal cancer (CRC) remains a significant global health burden, with KRAS mutations driving ∼40% of cases. Efficacy of recently approved, mutant-specific KRAS inhibitors is limited by intrinsic and adaptive resistance mechanisms. Pan-RAS inhibitors, such as ADT-007, offer broader therapeutic potential by targeting multiple RAS isoforms. Here, we evaluate ADT-007 in 3D bi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 96d0c556-59bd-598d-b34f-b15ae2d82fda
DOI: 10.1101/2025.02.25.640132

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor modelsDOI 10.1101/2025.02.25.640132Read

Molecular Profiling and High-Content Drug Screening of Metastatic Colorectal Cancer Organoids Reveal Evolutionary Mechanisms of Pan-KRAS Inhibitor ResistanceSemantic proximity Read

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screeningSemantic proximity Read

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.Semantic proximity Read

Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.Semantic proximity Read

Transcriptomic Analyses and Novel Organoid and Xenograft Modeling Reveals Potential Drug Sensitivities in a KRAS G12V-Mutant Colorectal Cancer Brain MetastasisSemantic proximity Read

A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal CancerSemantic proximity Read

Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer.Semantic proximity Read

Pathway-selective strategies reveal specific PI3K–mTOR inhibitors as key partners in KRAS G12D-targeted therapySemantic proximity Read

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.Semantic proximity Read

Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapySemantic proximity Read

A pan-KRAS degrader for the treatment of KRAS-mutant cancersSemantic proximity Read

Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in CRCSemantic proximity Read